Recent Updates
Recently added Catalysts
BMRN

BioMarin to Attend Upcoming Investor Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will...

Key Takeaway: SAN RAFAEL, Calif. , May 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Dan Spiegelman , Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on June 13, 2

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
7.9%
average across 8 past catalysts
Lead asset
Valoctocogene roxaparvovec
Phase 3 · Hemophilia A

Full Press Release Details

SAN RAFAEL, Calif. , May 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Dan Spiegelman , Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on June 13, 2017 at 1:20pm PT / 4:20pm ET , in Rancho Palos Verdes, California . To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com . A replay will also be archived on the site for at least one week following the event.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
Contacts:
Investors Media
Traci McCarty Debra Charlesworth
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (415) 455-7451
Last updated: May 31, 2017